EcoR1 Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-7,396,979
| Closed | -$435M | – | 68 |
|
|
2023
Q4 | $435M | Buy |
7,396,979
+1,648,580
| +29% | +$92.7M | 11.28% | 2 |
|
|
2023
Q3 | $250M | Buy |
+5,748,399
| New | +$205M | 8.45% | 3 |
|
|
2022
Q4 | – | Sell |
-1,015,572
| Closed | -$70.9M | – | 74 |
|
|
2022
Q3 | $70.9M | Buy |
+1,015,572
| New | +$75.1M | 2.09% | 13 |
|
|
2022
Q2 | – | Sell |
-500,622
| Closed | -$41.2M | – | 98 |
|
|
2022
Q1 | $41.2M | Buy |
+500,622
| New | +$51.2M | 1.29% | 21 |
|
|
2021
Q4 | – | Sell |
-464,298
| Closed | -$82.1M | – | 88 |
|
|
2021
Q3 | $82.1M | Hold |
464,298
| – | – | 2.86% | 8 |
|
|
2021
Q2 | $75M | Hold |
464,298
| – | – | 2.8% | 12 |
|
|
2021
Q1 | $79.5M | Hold |
464,298
| – | – | 3.53% | 9 |
|
|
2020
Q4 | $102M | Hold |
464,298
| – | – | 5.48% | 7 |
|
|
2020
Q3 | $77.1M | Buy |
464,298
+106,449
| +30% | +$14.6M | 5.5% | 6 |
|
|
2020
Q2 | $40.9M | Hold |
357,849
| – | – | 3.02% | 14 |
|
|
2020
Q1 | $27.5M | Buy |
357,849
+292,849
| +451% | +$26.3M | 2.87% | 14 |
|
|
2019
Q4 | $8.38M | Buy |
65,000
+20,779
| +47% | +$2M | 0.76% | 28 |
|
|
2019
Q3 | $3.44M | Sell |
44,221
-553,490
| -93% | -$51.9M | 0.44% | 26 |
|
|
2019
Q2 | $61.6M | Sell |
597,711
-402,289
| -40% | -$31.3M | 6.22% | 7 |
|
|
2019
Q1 | $73.3M | Buy |
1,000,000
+352,831
| +55% | +$24M | 6.76% | 3 |
|
|
2018
Q4 | $27.5M | Buy |
+647,169
| New | +$25.8M | 2.75% | 13 |
|
|
2018
Q1 | – | Sell |
-103,240
| Closed | -$1.88M | – | 38 |
|
|
2017
Q4 | $1.88M | Buy |
+103,240
| New | +$1.6M | 0.21% | 29 |
|
Other funds holding MRTX
EcoR1 Capital's MRTX Position: Q1 2024 in Review
EcoR1 Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,396,979 shares — an estimated $435M sold.
EcoR1 Capital first reported a position in MRTX in Q4 2017 and held it in 17 quarters. The position peaked at $435M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- EcoR1 Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- EcoR1 Capital sold 7,396,979 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $435M.
- EcoR1 Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
- EcoR1 Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $435M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.